YM-60828, a novel factor Xa inhibitor: Separation of its antithrombotic effects from its prolongation of bleeding time

By Sato K.   Kawasaki T.   Taniuchi Y.   Hirayama F.   Koshio H.   Matsumoto Y.  

European Journal of Pharmacology, Vol. 339, Iss. 2, 1997-11 ,pp. : 141-146

Elsevier

Access to resources Recommend Favorite

Antithrombotic effect of a humanized anti-GPIIb/IIIa monoclonal antibody, YM207, in a photochemically induced thrombosis model in monkeys

By Kaku S.   Kawasaki T.   Sakai Y.   Taniuchi Y.   Yano S.   Suzuki K.-i.   Terazaki C.   Kawamura K.   Masuho Y.   Satoh N.   Takenaka T.   Yanagi K.   Ohshima N.  

European Journal of Pharmacology, Vol. 279, Iss. 2, 1995-06 ,pp. : 115-121

Elsevier

Access to resources Recommend Favorite

Antithrombotic and hemostatic capacity of factor Xa versus thrombin inhibitors in models of venous and arteriovenous thrombosis

By Sinha U.   Ku P.   Malinowski J.   Zhu B.Y.   Scarborough R.M.   Marlowe C.K.   Wong P.W.   Lin P.H.   Hollenbach S.J.  

European Journal of Pharmacology, Vol. 395, Iss. 1, 2000-04 ,pp. : 51-59

Elsevier

Access to resources Recommend Favorite

Three paradigms of airway smooth muscle hyperresponsiveness in young guinea pigs

By Chitano Pasquale   Wang Lu   Murphy Thomas M.  

Canadian Journal of Physiology and Pharmacology, Vol. 85, Iss. 7, 2007-07 ,pp. : 715-726

NRC Research Press

Access to resources Recommend Favorite

The antithrombotic effects of CI-1031 (ZK-807834) and enoxaparin in a canine electrolytic injury model of arterial and venous thrombosis

By McClanahan T.B.   Hicks G.W.   Morrison A.L.   Peng Y.-W.   Janiczek-Dolphin N.   Mertz T.E.   Sullivan M.E.   Morser J.   Juneau P.L.   Leadley R.  

European Journal of Pharmacology, Vol. 432, Iss. 2, 2001-12 ,pp. : 187-194

Elsevier

Access to resources Recommend Favorite